Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of TAS-102 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Has provided written informed consent prior to performance of any study procedure.~* 2. Has definitive histologically or cytologically confirmed advanced or metastatic solid tumor.~* 3. Is able to take medications orally.~* 4. Has adequate organ function (bone marrow, kidney and liver).~* 5. Has Eastern Cooperative Group (ECOG) performance status of 0 or 1.~Exclusion Criteria:~* 1. Has received TAS-102.~* 2. Has suffered serious complications.~* 3. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies.~* 4. Has had prior gastrectomy.~* 5. Is a pregnant or lactating female or male who refused using birth control during the clinical trial period and within 6 months after discontinuation of study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).